Search
mRNA-1010
go.drugbank.com/drugs/DB22484Approved[L64058] The FDA approved mFLUSIVA on August 5, 2026 for active immunization against influenza in adults 50 years of age and older, making it the first mRNA-based influenza vaccine approved in the United … benefit to be confirmed in a postmarketing trial.
2,2'-Dibenzothiazyl disulfide
go.drugbank.com/drugs/DB14201Approved2,2'-Dibenzothiazyl disulfide is an accelerator used in the processing process for natural and synthetic rubber and plastic regeneration. It is also a known allergen and dermatological sensitizer.
Bisoctrizole
go.drugbank.com/drugs/DB11262ApprovedBisoctrizole is not approved by the FDA, but is approved in the EU and other parts of the world as a UV-filter in sunscreens, day care products and skin lightening products at a maximum concentration of
N-(2-Aminoethyl)-1-aziridineethanamine
go.drugbank.com/drugs/DB15643ExperimentalFirst described in the literature in 2004, N-(2-Aminoethyl)-1-aziridineethanamine is an experimental angiotensin converting enzyme 2 inhibitor investigated for its use in treating cardiovascular disease
Synonyms: N-(2-((2-Aminoethyl)amino)ethyl)aziridine, N-(2-aminoethyl)-1 aziridine-ethanamineCategories: Agents Acting on the Renin-Angiotensin SystemCholine C 11
go.drugbank.com/drugs/DB09277Approved[A32041] It was developed by MCPRF and FDA first approved in September 2012.
Nogapendekin alfa
go.drugbank.com/drugs/DB18740ApprovedInvestigational[L50592] This combination product was approved by the FDA on April 22, 2024, for the treatment of BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without … It is one of the active ingredients in Anktiva, a combination product also containing [inbakicept], where a single inbakicept is complexed with two nogapendekin alfa components.
Ribociclib
go.drugbank.com/drugs/DB11730ApprovedInvestigationalRibociclib was approved by the FDA in March 2017 under the brand name Kisqali.
Econazole
go.drugbank.com/drugs/DB01127ApprovedIt is used topically in dermatomycoses also orally and parenterally.
Mixtures: TRILON-E CREAMCrisaborole
go.drugbank.com/drugs/DB05219ApprovedInvestigationalThis non-steroidal agent is efficacious in improving disease severity, reducing the risk of infection and reducing the signs and symptoms in patients 2 years old and older. … It reduces the local inflammation in the skin and prevents further exacerbation of the disease with a good safety profile.
Iodamide
go.drugbank.com/drugs/DB08948ApprovedWithdrawnIodamide is a contrast medium molecule that is no longer marketed in the United States.
Categories: Compounds used in a research, industrial, or household setting